Select Publications
CGI’s founder, Dr. Chaganti, is a leading expert on the genetics and biology of lymphomas and germ cell tumors. His laboratory at Memorial Sloan-Kettering Cancer Center has produced more than 300 papers in the identification of genetic alterations associated with these cancers as highlighted:
Recurring chromosomal abnormalities in non-Hodgkin’s lymphoma: biologic and clinical significance. Chaganti RS, Nanjangud G, Schmidt H, Teruya-Feldstein J. Semin Hematol. 2000. 37(4):396-411.
Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. Blood. 2006. 107(6):2477-85.
Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.
Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Houldsworth J, Chaganti RS. Oncogene. 2001. 20(52):7686-93.
Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma. Chen W, Itoyama T, Chaganti RS. Genes Chromosomes Cancer. 2001. 32(3):281-4.
Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Chaganti RS. Genes Chromosomes Cancer. 2002. 35(4):318-28.
Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T. Am J Pathol. 2005. 166(4):1229-38.
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RS. Blood. 2004. 103(5):1862-8.
Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response. Houldsworth J, Petlakh M, Olshen AB, Chaganti RS. Leuk Lymphoma. 2008. 49(11):2170-80.
Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Nanjangud G, Rao PH, Teruya-Feldstein J, Donnelly G, Qin J, Mehra S, Jhanwar SC, Zelenetz AD, Chaganti RS. Cytogenet Genome Res. 2007. 118(2-4):337-44.
Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Nanjangud G, Rao PH, Hegde A, Teruya-Feldstein J, Donnelly G, Qin J, Jhanwar SC, Zelenetz AD, Chaganti RS. Blood. 2002. 99(7):2554-61.
Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, Terayu-Feldstein J, Cigudosa JC, Rao PH, Sanger WG, Weisenburger DD, Chaganti RS. Genes Chromosomes Cancer. 2002. 33(2):114-22.
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.
Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R, Dalla-Favera R. Nature. 2001. 412(6844):341-6.
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Rao PH, Houldsworth J, Palanisamy N, Murty VV, Reuter VE, Motzer RJ, Bosl GJ, Chaganti RS.
